ReviewNeuro-oncology advances
Targeting the tumor microenvironment in pediatric gliomas: Advances and future directions in immunotherapy.
Review in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Preclinical Activity of the B7-H3-Targeting Antibody-Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Ultrasound-Enhanced Drug Delivery in Pediatric Neuro-Oncology: A New Therapeutic Strategy.Pharmaceutics · 2026Review
- Metabolic Landscape and Emerging Therapeutic Potential in Pediatric and Adult Gliomas.International journal of molecular sciences · 2026Review
- Reprogramming tumor-associated macrophages in DMG/DIPG: emerging molecular and biophysical strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment (TME) is a critical determinant of tumor progression and therapeutic response in gliomas. While pediatric gliomas have historically been treated using strategies derived from the management of adult gliomas, emerging evidence reveals that pediatric gliomas possess a unique TME. The pediatric TME is distinct, characterized not only by differences in cellular composition but a lower mutational burden, diminished neoantigen presentation, and heightened immunosuppressive activity. The unique immune landscape, developmental trajectories, and immune escape mechanisms in the pediatric TME create barriers to effective therapy. Recent studies show promising results in novel and advanced therapeutic strategies, highlighting the potential for innovative immunotherapeutic approaches. Advances in methodologies for modeling the TME, including computational approaches and animal-based models, provide new insights into pediatric glioma biology. Utilization of computational models may provide opportunities to predict tumor response to specific therapies and tailor immunotherapy regimes to individuals, allowing for personalized care. Leveraging the unique features of the pediatric TME offers an opportunity to overcome current barriers to immunotherapy and develop more effective, age- and tumor-specific treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.